| Biomarker ID | 1353 |
| PMID | 24630684 |
| Year | 2014 |
| Biomarker | ERG |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.45 (95% CI: (1.62–3.72) |
| Effect on Pathways | Pathways include: Genes targeted by miRNAs in adipocytes WP1992, VEGFA-VEGFR2 Signaling Pathway WP3888 |
| Experiment | Active Survillence (AS) Progression For ERG Positive Vs ERG Negative samples |
| Type of Biomarker | Prognostic |
| Cohort | A total of 121 of 142 ERG-negative and 96 of 123 ERG-positive patients were included in the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | AS progression was defined as at least one of clinical progression, histopathologic progression, and PSA progression. Clinical progression was defined as increased tumour stage to ≥cT2b. For patients with a minimum of one rebiopsy, histopathologic progression was defined as GS ≥3 + 4 (or ≥4 + 3 if diagnosed with GS = 3 + 4), more than three rebiopsy cores with cancer, and/or bilateral cancer. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |